Alkermes plc ALKS

Company Overview

Alkermes plc is a global biopharmaceutical company focused on the development and commercialization of medicines for serious mental health and neurological disorders. The company operates primarily within the biopharmaceuticals and neuroscience therapeutics industries, with a strategic emphasis on proprietary, differentiated medicines that address unmet medical needs. Alkermes generates the majority of its revenue from branded pharmaceutical products rather than contract manufacturing or royalties.

Its primary revenue drivers are its commercial-stage products, including VIVITROL (for alcohol and opioid dependence), ARISTADA (for schizophrenia), and LYBALVI (for schizophrenia and bipolar I disorder). The company primarily serves psychiatric care providers, addiction treatment centers, hospitals, and specialty pharmacies, with a strong concentration in the U.S. healthcare market. Alkermes’ competitive positioning is anchored in its focus on long-acting injectable formulations and central nervous system (CNS) expertise, which create clinical differentiation and barriers to entry.

Alkermes was founded in 1987 and initially built its business around drug delivery technologies. A significant transformation occurred in 2011 when Alkermes plc was formed through the combination of Alkermes, Inc. and Elan Drug Technologies, establishing its current Ireland-based holding structure. Over time, the company exited its manufacturing-focused businesses to become a fully integrated, commercial-stage biopharmaceutical company centered on proprietary CNS medicines.